Tian-Tian Li1,2,3,#, Ming-Yao Meng1,2,4,#, Zheng Yu5, Yang-Fan Guo1,2,4, Yi-Yi Zhao1,2,4, Hui Gao1,2,4, Li-Li Yang1,2,3, Li-Rong Yang1,2,3, Meng-Yuan Chu1,2,3, Shan He1,2,4, Yuan Liu1,2,4, Xiao-Dan Wang1,2,4, Wen-Ju Wang1,2,4, Zong-Liu Hou1,2,4, Li-Wei Liao1,2,4,*, Lin Li1,2,4,*
Oncology Research, Vol.33, No.11, pp. 3447-3467, 2025, DOI:10.32604/or.2025.065394
- 22 October 2025
Abstract Background: Chimeric antigen receptor T (CAR-T) cell therapies have demonstrated significant clinical efficacy in hematological malignancies. However, their application to solid tumors remains substantially limited by multiple challenges, including the risk of off-target effects. Hence, optimizing CAR-T cells for stronger antigen binding is essential. Methods: In this study, we employed a classical anti-human endothelial growth factor receptor 2 (HER2) single-chain variable fragment (scFv) derived from trastuzumab, alongside an anti-HER2-13 scFv identified from a combinatorial cellular CAR library, for the construction of a third-generation CAR-T cell. Meanwhile, the phenotypes and both in vitro and in vivo functions of… More >
Graphic Abstract